Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 4, 2006, Pages 1072-1083

  Yeoh, Eric E ^a   Holloway, Richard H ^a   Fraser, Robert J ^b   Botten, Rochelle J ^a   Di Matteo, Addolorata C ^a   Butters, Julie ^a   Weerasinghe, Sujeeva ^a   Abeysinghe, Prasad ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

Hypofractionation; LENT SOMA toxicity scales; Prostate carcinoma; Quality of life; Radiation therapy

Indexed keywords

HYPOFRACTIONATION; LENT/SOMA TOXICITY SCALES; PROSTATE CARCINOMA; QUALITY OF LIFE;

ANTIGENS; COMPUTERIZED TOMOGRAPHY; DOSIMETRY; RADIOTHERAPY; TOXICITY;

TUMORS;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER RELAPSE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION URGENCY; DISEASE FREE SURVIVAL; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUESTIONNAIRE; RADIATION DOSE FRACTIONATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; UROGENITAL TRACT DISEASE;

ADULT; AGED; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33750297651     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.06.005     Document Type: Article

References (32)

1. Brenner D.J. Hypofractionation for prostate cancer radiotherapy-what are the issues?. (Editorial). Int J Radiat Oncol Biol Phys 57 (2003) 912-914
2. Fowler J., Chappell R., and Ritter M. Is the α/β for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
3. D'Souza W.D., and Thames H.D. Is the α/β for prostate tumors low?. Int J Radiat Oncol Biol Phys 51 (2001) 1-3
4. Lloyd-Davies R.W., Collins C.D., and Swan A.V. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). Urology 36 (1990) 107-111
5. Duncan W., Warde P., Catton C.N., et al. Carcinoma of the prostate: Results of radical radiotherapy (1970-1985). Int J Radiat Oncol Biol Phys 26 (1993) 203-210
6. Yeoh E., Fraser R.J., McGowan R.E., et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: Early results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys 55 (2003) 943-955
7. Kupelian P.A., Reddy C.A., Willoughby P.R., et al. Preliminary observations on biochemical relapse-free survival rates after short course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 904-912
8. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005) 6132-6138
9. Franklin C.I.V., Parker C.A., and Morton K.M. Late effects of radiation therapy for prostate carcinoma: The patient's perspective of bladder, bowel and sexual morbidity. Australis Radiol 42 (1998) 58-65
10. Denham J.W., O'Brien P.C., Dunstan R.H., et al. Is there more than one late radiation proctitis syndrome?. Radiother Oncol 51 (1999) 43-53
11. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
12. da Silva F.C., Fossa S.D., Aaronson H.K., et al. The quality of life of patients with newly diagnosed MI prostate cancer: Experience with EORTC clinical trial 30853. Eur J Cancer 32A (1996) 72-77
13. Cheung R., Tucker S.L., Lee A., et al. Dose response characteristics of low and intermediate risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61 (2005) 993-1002
14. Shipley W.U., Thames H.D., Sandler H.M., et al. Prediction of biochemical failure after radiation therapy for localized prostate cancer. JAMA 281 (1999) 1598-1604
15. Bentzen S.M., and Ritter M.A. The α/β ratio for prostate cancer: What is it, really?. Radiother Oncol 76 (2005) 1-3
16. Brenner D.J. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 60 (2004) 1013-1015
17. Sale C., Yeoh E., Scutter S., and Bezak E. 2 D versus 3 D radiation therapy for prostate carcinoma: A direct comparison of dose volume histograms. Acta Oncol 44 (2005) 348-354
18. Dawson L.A., Mah K., Franssen E., and Morton G. Target position variability throughout prostate radiotherapy. Int J Radiat Oncol Biol Phys 42 (1998) 1155-1161
19. Zelefsky M.J., Crean D., Mageras G.S., et al. Quantification and predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy. Radiother Oncol 50 (1999) 225-234
20. Dearnaley D.P., Khoo V.S., Norman A.R., et al. Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 353 (1999) 267-272
21. Kirkwood B.R., and Sterne J.A.C. Relaxing model assumptions. Essential medical statistics. 2nd ed. (2003), Blackwell Science, Oxford 341-354
22. Livsey J., Routledge J., Burns M., et al. Scoring of treatment-related late effects in prostate cancer. Radiother Oncol 65 (2002) 109-121
23. Smit W.G.J.M., Helle P.A., van Putten W.J.J., et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 18 (1990) 23-29
24. Schultheiss T.E., Hanks G.E., Hunt M.A., et al. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate. Int J Radiat Oncol Biol Phys 32 (1995) 643-649
25. Yeoh E., Botten R., Russo A., et al. Chronic effects of therapeutic irradiation for localised prostatic carcinoma on anorectal function. Int J Radiat Oncol Biol Phys 47 (2000) 915-924
26. O'Brien P.C., Franklin C.I.V., Poulsen M.G., et al. Acute symptoms, not rectally administered sucralfate predict for late radiation proctitis: Longer term follow-up of a Phase III trial-Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys 54 (2002) 442-449
27. Fowler J., Chappell R., and Ritter M. The prospects of new treatments for prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 3-5
28. Fowler H., and Leborgne. Acute radiation reactions in oral and pharyngeal mucosa: Tolerable levels in altered fractionation schedules. Radiother Oncol 69 (2003) 161-168
29. Orton C.G. High dose rate brachytherapy may be radiobiologically superior to low dose rate brachytherapy due to slow repair of late responding normal tissue cells. Int J Radiat Oncol 49 (2001) 183-189
30. Widmark A., Fransson P., and Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 74 (1994) 2520-2532
31. Di Matteo A., Botten R., Holloway R., Fraser R., and Yeoh E. 3 D versus 2 D RT for carcinoma of the prostate reduces anorectal motor dysfunction but not symptoms. Gastroenterology 128 Suppl (2005) A265
32. Yeoh E., Holloway R., Fraser R., et al. Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. Am J Gastroenterol 99 (2004) 361-369